DermaSensor, Inc
Raising nowOperatingDermasensor, Inc.
Biotech · Wilmington, DE
The only FDA-cleared AI diagnostic improving skin cancer detection for all clinicians
This company has an open fundraising round.
Financials
FY2024–FY2025 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round.
Cap table
Principal holders% as the filing states it, Sep 8, 2026
- Chris Dewey20%+of votes
- Cody Simmons20%+of votes
Sold to the crowd
- Reg CF · Jul 20264,727,948 Equity at $0.1569$741.8K· 327 investors
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
9 people
Health tech visionary. Built DermaSensor from concept to FDA clearance & TIME Best Invention. Former BD leader at Genentech & Silicon Valley medtech startup. Brown University Bioengineering & Economics BA. Brown University Bioengineering MS.
Clinical implementation expert. 10+ years in pediatric critical care at Columbia Presbyterian. Medical technology adoption across 100+ health systems in US & international markets. Guest lecturer, University of Miami. University of Miami Nursing BSN.
Marketing veteran. 25+ years in life sciences & financial services. Led 9+ product launches across global markets and generated $512M+ in lead opportunities at Abbott & American Express. Managed teams of 20. University of Phoenix Business Management BA.
Names and titles as disclosed on SEC Form C, WeFunder. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
never closed a Reg CF raise
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
- Form C/ASep 8, 20260001761384-26-000006EDGAR
- Form C/AJul 21, 20260001761384-26-000005EDGAR
- Form CJul 16, 20260001761384-26-000003EDGAR
- Form DDec 5, 20240001761384-24-000002EDGAR
- Form DDec 21, 20210001761384-21-000001EDGAR
- Form DMar 17, 20200001761384-20-000001EDGAR
- Form DDec 19, 20180001761384-18-000001EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.